Skip to main content

Table 3 Association of the expression level of molecular biomarkers with PFS/OS

From: Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy

Molecular biomarkers

High-grade serous carcinoma

Clear cell carcinoma

P e value

 

Cases (%)

P(OS)

P(PFS)

Cases (%)

P(OS)

P(PFS)

 

EGFR

113(100)

0.017

0.042

92(100)

0.012

0.267

0.195

 Negative

82(72.6)

  

59(64.1)

   

 Positive

31(27.4)

  

33(35.9)

   

HER2

113(100)

0.938

0.475

95(100)

0.001

0.200

0.006

 Negative

110(97.3)

  

83(87.4)

   

 Positive

3(2.7)

  

12(12.6)

   

PTEN

113(100)

0.323

0.397

93(100)

0.160

0.061

0.716

 Negative

99(87.6)

  

83(89.2)

   

 Positive

14(12.4)

  

10(10.8)

   

AURKA

113(100)

0.006

0.382

95(100)

0.022

0.035

0.582

 Negative

72(63.7)

  

57(60.0)

   

 Positive

41(36.3)

  

38(40.0)

   

BRCA1

113(100)

0.017

0.032

92(100)

0.823

0.424

0.007

 Negative

82(72.6)

  

50(54.3)

   

 Positive

31(27.4)

  

42(45.7)

   

BRCA2

113(100)

0.743

0.500

94(100)

0.466

0.929

0.054

 Negative

101(89.4)

  

75(79.8)

   

 Positive

12(10.6)

  

19(20.2)

   

PD-L1

113(100)

0.037

0.159

95(100)

0.773

0.425

0.064

 Negative

99(88.4)

  

75(78.9)

   

 Positive

13(11.6)

  

20 (21.1)

   
  1. A total of 113 cases of HGSC and 96 cases of CCC have both primary tumor immunohistochemistry results and survival information. However, the total number for each antibody does not add to up 96 in CCC group
  2. aChi-squared tests were performed for the difference of positive rates between HGSC and CCC groups
  3. Bold value denotes P with statistical significance